Cargando…

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor

In our previous work, we replaced the TRM (tryptophan-rich motif) of T20 (Enfuvirtide) with fatty acid (C16) to obtain the novel lipopeptide LP-40, and LP-40 displayed enhanced antiviral activity. In this study, we investigated whether the C16 modification could enhance the high-resistance barrier o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yue, Yu, Wenjiang, Geng, Xiuzhu, Zhu, Yuanmei, Chong, Huihui, He, Yuxian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223764/ https://www.ncbi.nlm.nih.gov/pubmed/35743078 http://dx.doi.org/10.3390/ijms23126638

Ejemplares similares

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19
por: He, Lin, et al.
Publicado: (2023)

Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy
por: Chen, Yue, et al.
Publicado: (2021)

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques
por: Chong, Huihui, et al.
Publicado: (2019)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
por: Zhu, Yuanmei, et al.
Publicado: (2021)

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors
por: Geng, Xiuzhu, et al.
Publicado: (2019)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide
por: Dingens, Adam S., et al.
Publicado: (2019)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)

Enfuvirtide antiretroviral therapy in HIV-1 infection
por: Kitchen, Christina MR, et al.
Publicado: (2008)

Enfuvirtide in therapy at patients with HIV-infection and tuberculosis
por: Kravchenko, AV, et al.
Publicado: (2010)

Preparation and evaluation of amphipathic lipopeptide‐loaded PLGA microspheres as sustained‐release system for AIDS prevention
por: Jin, Huijuan, et al.
Publicado: (2020)

HIV-1 Fusion Inhibitor Peptides Enfuvirtide and T-1249 Interact with Erythrocyte and Lymphocyte Membranes
por: Matos, Pedro M., et al.
Publicado: (2010)

Enfuvirtide−PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties
por: Cheng, Shuihong, et al.
Publicado: (2016)

Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif
por: Wu, Tong, et al.
Publicado: (2022)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

Sphingopeptides: dihydrosphingosine‐based fusion inhibitors against wild‐type and enfuvirtide‐resistant HIV‐1
por: Ashkenazi, Avraham, et al.
Publicado: (2012)

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
por: Yu, Danwei, et al.
Publicado: (2020)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41
por: Yan, Hongxia, et al.
Publicado: (2022)

Enfuvirtide biosynthesis in thermostable chaperone-based fusion
por: Zenin, Vladimir, et al.
Publicado: (2022)

Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy
por: Jin, Hongliang, et al.
Publicado: (2021)

Defective HIV-1 envelope gene promotes the evolution of the infectious strain through recombination in vitro
por: Wei, Huamian, et al.
Publicado: (2020)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor
por: Sun, Youxiang, et al.
Publicado: (2017)

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
por: Zhu, Yuanmei, et al.
Publicado: (2020)

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket
por: Zhang, Xiujuan, et al.
Publicado: (2018)

Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy
por: Zhu, Xiaojie, et al.
Publicado: (2015)

A Novel Class of Anti-HIV Agents with Multiple Copies of Enfuvirtide Enhances Inhibition of Viral Replication and Cellular Transmission In Vitro
por: Chang, Chien-Hsing, et al.
Publicado: (2012)

Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico
por: Huerta-García, Gloria, et al.
Publicado: (2014)

Fusion inhibitors and their evolving role during salvage antiretroviral therapy. Seven years of experience with enfuvirtide
por: Manfredi, Roberto
Publicado: (2010)

Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2
por: Zhu, Yuanmei, et al.
Publicado: (2023)

Short-course intensification with enfuvirtide in virologic failure: impact on intracellular HIV reservoir and on viral tropism (INNOVE study)
por: Ghosn, J, et al.
Publicado: (2010)

Impact of the HIV-1 env Genetic Context outside HR1–HR2 on Resistance to the Fusion Inhibitor Enfuvirtide and Viral Infectivity in Clinical Isolates
por: Baatz, Franky, et al.
Publicado: (2011)

Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability
por: Smith, Michele, et al.
Publicado: (2018)

A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections
por: Costiniuk, Cecilia, et al.
Publicado: (2023)

Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel
por: Li, Huanhuan, et al.
Publicado: (2023)

Characterization of Gp41 Polymorphisms in the Fusion Peptide Domain and T-20 (Enfuvirtide) Resistance-Associated Regions in Korean HIV-1 Isolates
por: Jang, Dai-Ho, et al.
Publicado: (2014)

Thermostable chaperone-based polypeptide biosynthesis: Enfuvirtide model product quality and protocol-related impurities
por: Zenin, Vladimir, et al.
Publicado: (2023)

Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification
por: Pechlivanis, Sonali, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_70n13i175md5o06dscnmlap2rt